| Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI. |
Alig AHS |
Heinemann V |
| ESMO Open 9 (9): 103677 |
Sonstige |
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
VOLFI |
AIO-KRK-0109 |
| www.esmoopen.com/article/S2059-7029(24)01446-7/fulltext |
|
|
| Durvalumab and tremelimumab versus doxorubicin in previously untreated patients with advanced or metastatic soft tissue sarcoma: Patient-reported outcomes (PROs) of the randomized phase II MEDISARC study (AIO-STS-0415). |
|
|
| J Clin Oncol 42 (suppl 16) |
|
2024 |
|
Weichteilsarkome
|
|
|
| ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.11519 |
|
|
| Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial. |
|
|
| JAMA Oncol |
|
2024 |
|
Urothelkarzinom
|
|
|
| doi.org/10.1001/jamaoncol.2024.0938 |
|
|
| Molecular testing in patients with advanced NSCLC from 2016-23 (Prospective German Registry CRISP, AIO-TRK-0315). |
|
|
| Ann Oncol 35 (Supplement 2, 1388P): 870 |
|
2024 |
|
Thorakale Onkologie
|
|
|
| doi.org/10.1016/j.annonc.2024.08.1443 |
|
|
| Interim analysis from the multicenter ROSE study: Radiation during osimertinib treatment safety and efficacy cohort. |
|
|
| Ann Oncol 35 (Supplement 2, 1266P): 810-1 |
|
2024 |
|
Thorakale Onkologie
|
|
|
| doi.org/10.1016/j.annonc.2024.08.1323 |
|
|
| Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315) |
|
|
| Int J Cancer 154 (11): 1967-78 |
|
2024 |
|
Thorakale Onkologie
|
|
|
| doi.org/10.1002/ijC.34868 |
|
|
| Anemia Diagnosis and Therapy in Malignant Diseases, Implementation of Guidelines, A Representative Study. |
|
|
| Support Care Cancer 32:113 |
|
2024 |
|
Supportive Therapie
|
|
|
| doi.org/10.1007/s00520-023-08267-4 |
|
|
| Exploratory biomarker analysis of the NEONAX trial for response prediction to perioperative (PO) and adjuvant (A) Gem-nabPac chemotherapy (CTX) in resectable PDAC patients (rPDAC Pts). |
|
|
| Ann Oncol 35 (Supplement 2, 1505P): 922-3 |
|
2024 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1016/j.annonc.2024.08.1568 |
|
|
| Exploration of circulating free bacterial DNA as a biomarker for therapy response in metastatic and locally advanced pancreatic cancer patients treated with systemic chemotherapy. |
|
|
| Ann Oncol 35 (Supplement 2, 1510P): 924 |
|
2024 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1016/j.annonc.2024.08.1573 |
|
|
| Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma |
|
|
| J Clin Oncol 42 (suppl 16) |
|
2024 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1200/JCO.2024.42.16_suppl.TPS4203 |
|
|
